Health Care
featured
The health-care industry is looking to harness big data, but finding the right workers isn't always easy. In some cases, companies are making acquisitions to bring talent in-house.
» Read More
More
-
On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
-
Recently I blogged about Merck advertising its cervical cancer vaccine Gardasil to a captive audience during trailers for the "Sex and the City" movie.
-
Yesterday while covering the press conference about the new study on Merck and Schering-Plough's Vytorin I quoted the lead researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway, who said--and this is a direct quote: "However, we had a disturbing finding when we looked at safety."
-
The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005.
-
arr's Chairman and CEO Bruce Downey told me Teva's CEO Schlomo Yanai made the first move. But it didn't happen in a long-distance phone call from Tel Aviv to New Jersey. They say they were at an industry conference in Palm Beach outside some burger joint when the subject came up.
-
Symmetry Medical proves investors can speculate and play defense at the same time.
-
The researchers say the most vulnerable region to kidney stone outbreaks will probably be in the ever-hotter Southeast. "If, however, the risk suddenly climbs steeply at some threshold temperature, a band stretching from Kentucky to northern California would likely see the most new cases."
-
I am out in the field today shooting a story in Boston for the upcoming big Alzheimer's meeting the end of this month. But I wanted to pass along this nugget dug up by Pharmalot's Ed Silverman: The Pfizer Exec And The $300K Helicopter Bill.
-
More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.
-
Figuring out why states fared poorly in America’s Top States For Business 2008 takes a bit less work than determining why others did well. It usually comes down to performance and scoring in three key categories, and they happen to be the three with the most impact on the weighting and the overall rankings. Here's the ten worst -- and why.
-
After a knee-jerk reaction to the downside after the closing bell yesterday to the surprising four-cent miss by Genentech, the shares are rallying big time in the early regular trading session.
-
The chief executive explains why her stock has taken such a hit.
-
Like so many people who knew Bobby Murcer or were fans of his, I was so sad to hear the news that he had passed away. I didn't know the man. And I only have vague childhood memories of then-Dodger Stadium announcer John Ramsey saying, "Bobby Murcer", when the "Yankee for Life" was playing for the Giants and Cubs at Chavez Ravine.
-
Diagnostic firms DiaSorin and Biomerier and oil storage company Vopak are three small-cap stocks with promising growth prospects, Dave Dudding, fund manager from Threadneedle Investments, told CNBC.
-
As healthcare comes back in fashion, this stock stands poised to profit.
-
A few weeks ago I blogged about a couple analysts cautioning investors that shares of Irish drugmaker Elan would be volatile surrounding the Alzheimer's conference the end of this month.That has certainly proven to be the case, especially today as the second firm this week initiates coverage of the stock, but this time with a "Sell" rating.
-
Figuring out why states fared poorly in America’s Top States For Business 2008 takes a bit less work than determining why others did well. It usually comes down to performance and scoring in three key categories, and they happen to be the three with the most impact on the weighting and the overall rankings. Here's the ten worst -- and why.
-
Big pharma makes strange bedfellows. Pfizer, Merck and Eli Lilly this morning announced they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC firm PureTech Ventures.
-
One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!
-
Crowding into commodities by investors fleeing stocks will contribute to increased volatility, Peter Toogood, chief investment officer at Crosby Forsyth, told "Squawk Box Europe" on Wednesday.